Video

ROME – The rate of adverse events in patients with juvenile idiopathic arthritis appears to climb with the use of more than one biologic agent over time, Dr. Joost Swart reported at the European Congress of Rheumatology.

When used with methotrexate, the rate of adverse events doubled among users of one biologic agent when compared against patients who used methotrexate alone, and tripled among users of more than one biologic, according to the study of nearly 6,000 patients in the Pharmachild registry.

Dr. Swart, a pediatric rheumatologist/immunologist in the department of pediatric immunology and rheumatology in the Wilhelmina Children’s Hospital at University Medical Center Utrecht (the Netherlands), said in an interview that while patients who took a biologic had a higher rate of ever using systemic corticosteroids, it’s not clear whether that contributed to the difference in adverse events.

jevans@frontlinemedcom.com

ROME – The rate of adverse events in patients with juvenile idiopathic arthritis appears to climb with the use of more than one biologic agent over time, Dr. Joost Swart reported at the European Congress of Rheumatology.

When used with methotrexate, the rate of adverse events doubled among users of one biologic agent when compared against patients who used methotrexate alone, and tripled among users of more than one biologic, according to the study of nearly 6,000 patients in the Pharmachild registry.

Dr. Swart, a pediatric rheumatologist/immunologist in the department of pediatric immunology and rheumatology in the Wilhelmina Children’s Hospital at University Medical Center Utrecht (the Netherlands), said in an interview that while patients who took a biologic had a higher rate of ever using systemic corticosteroids, it’s not clear whether that contributed to the difference in adverse events.

jevans@frontlinemedcom.com

ROME – The rate of adverse events in patients with juvenile idiopathic arthritis appears to climb with the use of more than one biologic agent over time, Dr. Joost Swart reported at the European Congress of Rheumatology.

When used with methotrexate, the rate of adverse events doubled among users of one biologic agent when compared against patients who used methotrexate alone, and tripled among users of more than one biologic, according to the study of nearly 6,000 patients in the Pharmachild registry.

Dr. Swart, a pediatric rheumatologist/immunologist in the department of pediatric immunology and rheumatology in the Wilhelmina Children’s Hospital at University Medical Center Utrecht (the Netherlands), said in an interview that while patients who took a biologic had a higher rate of ever using systemic corticosteroids, it’s not clear whether that contributed to the difference in adverse events.

jevans@frontlinemedcom.com

Dr. Jashin Wu discusses results from a study on tumor necrosis factor (TNF) inhibitors for psoriasis and myocardial infarction risk. The study evaluated TNF inhibitor use, oral therapy and phototherapy, and topical therapy. He also reviews results from another study that looked at heart attacks, stroke, and cardiovascular death with biologics, methotrexate, retinoids, cyclosporine, and other therapies for psoriasis. If we want to believe there is a reduction of cardiovascular risk with TNF inhibitors, what's the mechanism? Dr. Wu presents several theories.

Dr. Jashin Wu discusses results from a study on tumor necrosis factor (TNF) inhibitors for psoriasis and myocardial infarction risk. The study evaluated TNF inhibitor use, oral therapy and phototherapy, and topical therapy. He also reviews results from another study that looked at heart attacks, stroke, and cardiovascular death with biologics, methotrexate, retinoids, cyclosporine, and other therapies for psoriasis. If we want to believe there is a reduction of cardiovascular risk with TNF inhibitors, what's the mechanism? Dr. Wu presents several theories.

Dr. Jashin Wu discusses results from a study on tumor necrosis factor (TNF) inhibitors for psoriasis and myocardial infarction risk. The study evaluated TNF inhibitor use, oral therapy and phototherapy, and topical therapy. He also reviews results from another study that looked at heart attacks, stroke, and cardiovascular death with biologics, methotrexate, retinoids, cyclosporine, and other therapies for psoriasis. If we want to believe there is a reduction of cardiovascular risk with TNF inhibitors, what's the mechanism? Dr. Wu presents several theories.

VA patients with breast cancer are often located in sparsely populated rural areas throughout the U.S. According to Sarah Colonna, MD, of the George E. Whalen VA in Salt Lake City, Utah, geographic differences must be accounted for when physicians create treatment plans.

“Forty percent of veterans are considered rural whereas only 16% of the general population is considered rural,” Dr. Colonna said. “We were exploring whether rural women were getting the appropriate care and appropriate treatment compared with their urban counterparts.”

VA patients with breast cancer are often located in sparsely populated rural areas throughout the U.S. According to Sarah Colonna, MD, of the George E. Whalen VA in Salt Lake City, Utah, geographic differences must be accounted for when physicians create treatment plans.

“Forty percent of veterans are considered rural whereas only 16% of the general population is considered rural,” Dr. Colonna said. “We were exploring whether rural women were getting the appropriate care and appropriate treatment compared with their urban counterparts.”

VA patients with breast cancer are often located in sparsely populated rural areas throughout the U.S. According to Sarah Colonna, MD, of the George E. Whalen VA in Salt Lake City, Utah, geographic differences must be accounted for when physicians create treatment plans.

“Forty percent of veterans are considered rural whereas only 16% of the general population is considered rural,” Dr. Colonna said. “We were exploring whether rural women were getting the appropriate care and appropriate treatment compared with their urban counterparts.”

PHILADELPHIA – The topic of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) was discussed at length by Dr. Zobair M. Younossi, a physician with the Inova Health System of northern Virginia, at the second annual Digestive Diseases: New Advances meeting on Saturday.

Both NAFLD and NASH are becoming increasingly prevalent conditions in the United States, and proper diagnostic and treatment options are therefore becoming more necessary. To that end, Dr. Younossi talked about a number of existing and emerging options that physicians and clinicians can choose from.

“[NAFLD] is a very common disease, its prevalence in the United States is about 20%-25%,” said Dr. Younossi. “When you look at certain individuals who are at-risk, such as those who undergo bariatric surgery, the prevalence goes up to 90%-95%, and diabetics have a prevalence of about 50%-65%.”

When you look at the prevalence of NASH, the progressive form of NAFLD, it goes down to only about 2%-3%; however, said Dr. Younossi, “when you put this in the context of hepatitis C, which has a prevalence of about 1.8%, you see that it’s becoming quite common.”

In this video interview, Dr. Younossi discusses his overview of management options for NAFLD and related conditions, as well as his take on new and emerging options that he feels clinicians should be keeping their eye on.

Dr. Younossi has been a consultant to Gilead, AbbVie, Bristol-Myers Squibb, GlaxoSmithKline, Intercept, and Salix.

dchitnis@frontlinemedcom.com

PHILADELPHIA – The topic of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) was discussed at length by Dr. Zobair M. Younossi, a physician with the Inova Health System of northern Virginia, at the second annual Digestive Diseases: New Advances meeting on Saturday.

Both NAFLD and NASH are becoming increasingly prevalent conditions in the United States, and proper diagnostic and treatment options are therefore becoming more necessary. To that end, Dr. Younossi talked about a number of existing and emerging options that physicians and clinicians can choose from.

“[NAFLD] is a very common disease, its prevalence in the United States is about 20%-25%,” said Dr. Younossi. “When you look at certain individuals who are at-risk, such as those who undergo bariatric surgery, the prevalence goes up to 90%-95%, and diabetics have a prevalence of about 50%-65%.”

When you look at the prevalence of NASH, the progressive form of NAFLD, it goes down to only about 2%-3%; however, said Dr. Younossi, “when you put this in the context of hepatitis C, which has a prevalence of about 1.8%, you see that it’s becoming quite common.”

In this video interview, Dr. Younossi discusses his overview of management options for NAFLD and related conditions, as well as his take on new and emerging options that he feels clinicians should be keeping their eye on.

Dr. Younossi has been a consultant to Gilead, AbbVie, Bristol-Myers Squibb, GlaxoSmithKline, Intercept, and Salix.

dchitnis@frontlinemedcom.com

PHILADELPHIA – The topic of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) was discussed at length by Dr. Zobair M. Younossi, a physician with the Inova Health System of northern Virginia, at the second annual Digestive Diseases: New Advances meeting on Saturday.

Both NAFLD and NASH are becoming increasingly prevalent conditions in the United States, and proper diagnostic and treatment options are therefore becoming more necessary. To that end, Dr. Younossi talked about a number of existing and emerging options that physicians and clinicians can choose from.

“[NAFLD] is a very common disease, its prevalence in the United States is about 20%-25%,” said Dr. Younossi. “When you look at certain individuals who are at-risk, such as those who undergo bariatric surgery, the prevalence goes up to 90%-95%, and diabetics have a prevalence of about 50%-65%.”

When you look at the prevalence of NASH, the progressive form of NAFLD, it goes down to only about 2%-3%; however, said Dr. Younossi, “when you put this in the context of hepatitis C, which has a prevalence of about 1.8%, you see that it’s becoming quite common.”

In this video interview, Dr. Younossi discusses his overview of management options for NAFLD and related conditions, as well as his take on new and emerging options that he feels clinicians should be keeping their eye on.

Dr. Younossi has been a consultant to Gilead, AbbVie, Bristol-Myers Squibb, GlaxoSmithKline, Intercept, and Salix.

dchitnis@frontlinemedcom.com

ROME – Changes in the methylation status of particular genes in psoriatic arthritis patients might provide the ability to predict failure to respond to tumor necrosis factor-alpha inhibitors, according to preliminary research in 41 psoriatic arthritis patients.

Two genes stood out to the researchers from Memorial University of Newfoundland, St. John’s: TNFRSF1B and CD70. Patients who had methylation changes to those genes were more likely to have secondary failure of TNF inhibitors, said Dr. Proton Rahman, professor of internal medicine at the university and coinvestigator on the study.

It will be necessary to conduct validation studies of the results in larger numbers of patients, as well as functional studies of the effects of methylation changes on the expression of those genes and their proteins, he said in a video interview at the European Congress of Rheumatology.

jevans@frontlinemedcom.com

ROME – Changes in the methylation status of particular genes in psoriatic arthritis patients might provide the ability to predict failure to respond to tumor necrosis factor-alpha inhibitors, according to preliminary research in 41 psoriatic arthritis patients.

Two genes stood out to the researchers from Memorial University of Newfoundland, St. John’s: TNFRSF1B and CD70. Patients who had methylation changes to those genes were more likely to have secondary failure of TNF inhibitors, said Dr. Proton Rahman, professor of internal medicine at the university and coinvestigator on the study.

It will be necessary to conduct validation studies of the results in larger numbers of patients, as well as functional studies of the effects of methylation changes on the expression of those genes and their proteins, he said in a video interview at the European Congress of Rheumatology.

jevans@frontlinemedcom.com

ROME – Changes in the methylation status of particular genes in psoriatic arthritis patients might provide the ability to predict failure to respond to tumor necrosis factor-alpha inhibitors, according to preliminary research in 41 psoriatic arthritis patients.

Two genes stood out to the researchers from Memorial University of Newfoundland, St. John’s: TNFRSF1B and CD70. Patients who had methylation changes to those genes were more likely to have secondary failure of TNF inhibitors, said Dr. Proton Rahman, professor of internal medicine at the university and coinvestigator on the study.

It will be necessary to conduct validation studies of the results in larger numbers of patients, as well as functional studies of the effects of methylation changes on the expression of those genes and their proteins, he said in a video interview at the European Congress of Rheumatology.

jevans@frontlinemedcom.com

CHICAGO – Anastrozole may top tamoxifen in reducing the risk of disease recurrence in postmenopausal ductal carcinoma in situ (DCIS), particularly in younger women, but which drug holds a cost advantage?

“How much do you want to pay in dollars or in side effects to achieve the extra benefit is an individual decision that a woman has to make with her physician,” said Dr. Richard Margolese, professor of surgical oncology at Jewish General Hospital, McGill University, Montreal.

In a video interview at the annual meeting of the American Society of Clinical Oncology, Dr. Margolese discussed the cost and side effect considerations that could determine a decision between anastrozole and tamoxifen.

trudd@frontlinemedcom.com

CHICAGO – Anastrozole may top tamoxifen in reducing the risk of disease recurrence in postmenopausal ductal carcinoma in situ (DCIS), particularly in younger women, but which drug holds a cost advantage?

“How much do you want to pay in dollars or in side effects to achieve the extra benefit is an individual decision that a woman has to make with her physician,” said Dr. Richard Margolese, professor of surgical oncology at Jewish General Hospital, McGill University, Montreal.

In a video interview at the annual meeting of the American Society of Clinical Oncology, Dr. Margolese discussed the cost and side effect considerations that could determine a decision between anastrozole and tamoxifen.

trudd@frontlinemedcom.com

CHICAGO – Anastrozole may top tamoxifen in reducing the risk of disease recurrence in postmenopausal ductal carcinoma in situ (DCIS), particularly in younger women, but which drug holds a cost advantage?

“How much do you want to pay in dollars or in side effects to achieve the extra benefit is an individual decision that a woman has to make with her physician,” said Dr. Richard Margolese, professor of surgical oncology at Jewish General Hospital, McGill University, Montreal.

In a video interview at the annual meeting of the American Society of Clinical Oncology, Dr. Margolese discussed the cost and side effect considerations that could determine a decision between anastrozole and tamoxifen.

trudd@frontlinemedcom.com